Johnson & Johnson (NYSE:JNJ) receives a stock grade upgrade to “Buy” by Johnson Rice.
The company is scheduled to participate in the Goldman Sachs 46th Annual Global Healthcare Conference.
Current stock price reflects a slight decrease, with a significant market capitalization of approximately $352.71 billion.
Johnson & Johnson (NYSE:JNJ) is a well-known multinational corporation that operates in the pharmaceutical, medical devices, and consumer health sectors. The company is a leader in the healthcare industry, competing with other giants like Pfizer and Merck. On May 15, 2025, Johnson Rice upgraded JNJ’s stock grade to “Buy,” with the stock priced at $146.36 at the time of the announcement. Despite this upgrade, the action remains as “hold.”
Johnson & Johnson is set to participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 11th, 2025. The company’s management will engage in a Fireside Chat at 3:20 p.m. Eastern Time. Investors can listen to the live audio webcast on the Johnson & Johnson investor website, with a replay available 48 hours after the event. This participation could provide insights into the company’s future strategies and performance.
The current stock price of JNJ is $146.36, reflecting a decrease of 1.40% or $2.08. Today, the stock has traded between $146.12 and $148.82. Over the past year, JNJ’s stock has reached a high of $169.99 and a low of $140.68. This fluctuation indicates the stock’s volatility and the market’s response to various factors affecting the company and the healthcare sector.
Johnson & Johnson has a substantial market capitalization of approximately $352.71 billion, highlighting its significant presence in the market. The trading volume for the day is 10,212,110 shares on the New York Stock Exchange (NYSE). This high trading volume suggests strong investor interest and activity in the stock, possibly influenced by the recent upgrade and upcoming conference participation.
